Significant advances have been made in chimeric antigen receptor T (CAR-T)-cell therapy for the treatment of recurrent or refractory B-cell hematologic malignancies. However, CAR-T-cell therapy has not yet achieved comparable success in the management of
Treating neoplastic diseases with antibody-cytotoxin conjugate (duocarmycins); integrins; 3-[5-(1-(3-aminopropyl)indole-2-carbonyl)aminoindole-2-carbonyl]-1-(chloromethyl)-5-hydroxy-1,2-dihydro-3H-benz[e]indoledoi:US20080267981 A1Methods for treating a neoplastic disease with an antibody-...
BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target immunotherapy. Bispecific CARs are proposed to
Five groups of alkylating agents have been utilized in the treatment of neoplastic diseases – the nitrogen mustards, ethyleneamines, alkyl sulphonates (busulphan, dimethylbusulphan), the nitrosoureas and the triazines (dacarbazine, procarbazine).968 As nearly as can be ascertained from the availa...
Since then, extensive research activities have been ongoing globally on different hematologic and solid tumors to assess the safety and efficacy of CAR-T therapy for these diseases. Limitations to CAR-T therapy became apparent from, e.g., the relapse in up to 60% of patients and certain side...
Engineered antigen receptors are revolutionizing the treatment of blood cancers and show promise in cell therapies treating a wide range of other diseases1. The most clinically advanced of these technologies are chimeric antigen receptors (CARs), synthetic T cell receptors most often comprised of an ...
Administration of ATG in combination with rituximab, which binds to the co-expressed CAR T-cell transduction/selection marker RQR8, led to CAR T-cell depletion. Thus, we here provide the first proof of concept for the generation and preclinical efficacy of CAR T-cells directed against CD117-...
36. The composition of claim 33, wherein the medical condition is a cancer, and the cancer is lymphoma, leukemia, non-Hodgkin's lymphoma, acute lympho blastic leukemia, chronic lymphoblastic leukemia, chronic lymphocytic leukemia, or B cell-associated autoimmune diseases. 37. The composition of ...
Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells 2022, Molecular Therapy Methods and Clinical Development Show abstract EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target 2022, Blood Show abstract Therapeutic trials for long COVI...
ARTICLE https://doi.org/10.1038/s41467-020-20488-3 OPEN CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells Mario Bunse 1,7, Janina Pfeilschifter1,7, Julia Bluhm2, Maria Zschummel1, Jara J. Joedicke 1, Anthea Wirges2, ...